CRISPR-Cas9 IL2RG Locus Targeting for SCID-X1 Gene Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current gene therapy approaches for X-linked Severe Combined Immunodeficiency (SCID-X1) face challenges in achieving clinically relevant targeted integration frequencies, functional protein expression, and safety, particularly due to risks of leukemic events and genotoxicity associated with semi-random viral vector integration.
Innovation Solution
The method involves using homologous recombination-mediated genome editing with CRISPR-Cas9 to introduce a full-length, functional IL2RG cDNA at the endogenous IL2RG locus in hematopoietic stem and progenitor cells, ensuring precise integration and expression under native regulatory elements, combined with AAV6 viral vectors for delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If semi-random viral vector integration is used for gene therapy, then functional IL2RG protein expression is achieved, but genotoxicity and leukemic transformation risk increase
Solution Approach 1:
The patent uses AAV6 viral vectors as intermediaries to deliver CRISPR-Cas9 components and homology templates to HSPCs. The AAV6 vector serves as a safe delivery vehicle that enables precise genome editing without random integration, thus achieving functional protein expression while minimizing genotoxicity risks associated with traditional retroviral integration methods
Solution Approach 2:
The patent replaces the mechanical/random integration process of traditional viral vectors with a precision-based CRISPR-Cas9 genome editing system. This substitution allows targeted integration of the functional IL2RG cDNA at the endogenous locus through homology-directed repair, eliminating the genotoxicity inherent in semi-random integration while maintaining therapeutic efficacy
2Object-affected harmful factors
If targeted genome editing is used to achieve precise integration, then genotoxicity risk is reduced, but integration frequency and functional expression may be insufficient
Solution Approach 1:
The patent performs preliminary actions by first delivering CRISPR-Cas9 components to create double-strand breaks at the target locus, then providing homology templates for precise repair. This two-step preliminary preparation ensures that when integration occurs, it happens at the correct location with high frequency and proper expression levels, overcoming the limitation of low integration efficiency
Solution Approach 2:
The patent optimizes multiple parameters including AAV6 vector multiplicity of infection (MOI), CRISPR-Cas9 component ratios, homology template design, and cell culture conditions. By systematically adjusting these parameters, the patent achieves both high targeted integration frequency and functional protein expression while maintaining safety
3Reliability
If allogeneic hematopoietic cell transplant is performed, then immune reconstitution is achieved, but graft versus host disease and survival rate decrease
Solution Approach 1:
The patent enables patients to receive their own genetically corrected HSPCs (autologous transplantation). The patient's cells are harvested, genetically modified ex vivo to correct the IL2RG mutation, and then reinfused. This self-service approach eliminates the need for allogeneic donors, thereby avoiding graft versus host disease while achieving complete immune reconstitution with 100% HLA matching
4Productivity
If more viral vectors are used to increase integration frequency, then targeted integration improves, but insertional oncogenesis risk increases
Solution Approach 1:
The patent replaces the random integration mechanism of traditional viral vectors with CRISPR-Cas9-mediated homology-directed repair. This substitution ensures that integration occurs only at the specific endogenous IL2RG locus with precise control, achieving high integration frequency without the insertional oncogenesis risk associated with increased viral vector dosing
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach achieves high frequencies of targeted integration and functional IL2RG protein expression, demonstrating safety and efficacy in rescuing immune defects in SCID-X1 patients with reduced risk of genotoxicity and leukemic transformation.
Implementation Method 1
The highest frequencies of GE are achieved using an engineered nuclease to create a site-specific double-strand break (DSB) in the cell's genomic DNA
Implementation Method 2
When the DSB is repaired by non-homologous end joining (NHEJ), small insertions and deletions (INDELs) can be created at a specific genomic target site
Implementation Method 3
when the DSB is repaired by either HR (using a classic gene-targeting donor vector) or by single-stranded template repair
Data Source
AI summary
The present disclosure provides methods and compositions for treating SCID-X1 in subjects, comprising genetically modifying cells from the subjects ex vivo by integrating a full-length, codon-optimized IL2RG cDNA at the endogenous IL2RG locus.